Purchase this article with an account.
J.T. DellaCroce, M. Riazi Esfahani, A.A. Kazi, G.A. Peyman, E. Aydin; Intravitreal Toxicity of Garenoxacin . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5561.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To assess the retinal toxicity of various concentrations of intravitreally injected garenoxacin. Methods: Twenty eyes of twenty New Zealand albino rabbits were used for this study. The animals were anesthetized and treated in accordance with the ARVO statement for the use of animals in ophthalmic and visual research. Garenoxacin was titrated using distilled water to the following concentrations: 4000 µg/0.1 ml, 2000 µg/0.1 ml, 1000 µg/0.1 ml, 400 µg/0.1 ml, 200 µg/0.1 ml, and 100 µg/0.1 ml. Each of these concentrations was injected intravitreally (0.1 ml) into 3 rabbit eyes. Three eyes were used as control and received 0.1 ml of balanced salt solution. All animals were examined before and after injection using the indirect ophthalmoscope and slit–lamp biomicroscopy. Electroretinography (ERG) was performed on all animals prior to intravitreal injection and 14 days after injection. The animals were euthanized and the eyes were enucleated and examined with light microscopy. Results: No ERG changes or signs of retinal toxicity on slit–lamp examination, indirect ophthalmoscopy, or light microscopy were seen in any of the eyes 14 days after intravitreal injection of 4000 µg of garenoxacin or less. Conclusions: Garenoxacin injected intravitreally appears safe at concentrations of 4000 µg/0.1 ml or less. These doses are several times more than the minimum inhibitory concentration required for the most resistant Gram–positive endophthalmitis isolates and it may be considered as an efficient drug in treatment of bacterial endophthalmitis.
This PDF is available to Subscribers Only